Histone Deacetylase Inhibitor

No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.

The addition of romidepsin to CHOP did not improve PFS in patients with peripheral T-cell lymphoma, according to an analysis presented at ASH Annual Meeting and Exposition.